Overview

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
0
Participant gender:
Female
Summary
This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
GlaxoSmithKline
Criteria
Inclusion criteria:

- Confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal
carcinoma.

- Has received one prior platinum-based chemotherapy regimen(cisplatin,carboplatin, or
oxaliplatin).

- Has psychological, familial, sociological or geographical condition that does not
permit compliance with the protocol.

- Is on a specifically prohibited medication or requires these medications during
treatment with GW786034.

Exclusion criteria:

- Has had any surgery, chemotherapy, hormonal therapy, biologic, immunotherapy, or
radiotherapy with in the last 28 days and has not recovered from such prior therapy.

- Poorly controlled hypertension(systolic 140mmHg or higher or Diastolic 90mmHg or
higher).

- Currently taking warfarin.

- Low molecular weight heparin and low-dose warfarin(1mg per day)is permitted.